Trial · NCT07362836
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
NCT07362836, Phase 3, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS). Trials, record NCT07362836. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07362836
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
- NCT number
- NCT07362836
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 224 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Colorectal Cancer
- Interventions
- fruquintinib+chemotherapy, bevacizumab+chemotherapy
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months | Progression-Free Survival (PFS) is a time-to-event outcome commonly used as a primary or secondary endpoint in oncology clinical trials. It quantifies the duration a patient lives without disease progression or death, providing an early indicator of treatment efficacy. |
| Secondary | Objective Response Rate | ORR will be assessed up to Week 24 after randomization | ORR (Objective Response Rate) refers to the proportion of patients in a clinical trial whose tumor burden is reduced by a predefined amount, specifically achieving either a Complete Response (CR) or Partial Response (PR), as assessed by the investigator based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria. |
| Secondary | Disease Control Rate | DCR will be assessed up to Week 24 after randomization. | Disease Control Rate (DCR) is defined as the percentage of patients whose disease responds to treatment (i.e., achieves Complete Response (CR) or Partial Response (PR)) or remains stable (Stable Disease, SD) over a defined period of time. It reflects the proportion of patients who experience tumor shrinkage or disease stabilization without progression. |
| Secondary | Overall Survival | From date of randomization until the date of death from any cause, assessed up to 60 months | Overall Survival (OS) is the most definitive and direct measure of clinical benefit in cancer trials. It is defined as the time from randomization (or start of treatment) to death from any cause. This endpoint captures the ultimate outcome of interest: whether a patient is alive. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07362836
GET https://conductscience.org/api/trials/v1/NCT07362836/registered